Sequoia Capital Israel

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Generation Lab aims to enhance human health by developing the first clinically applicable test that assesses an individual's biological age progression and disease risk. This enables longer, healthier lives.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Rhegen is engaged in the research and development of mRNA medicine and gene therapy, focusing on synthetic biology technologies to create innovative mRNA drugs and vaccines. The company specializes in platform technologies essential for nucleic acid therapeutics, including mRNA design, synthesis, and non-carrier delivery methods. Rhegen applies these advancements to drug research and development, targeting various clinical indications such as functional protein defects, cancer, and infectious diseases. With a commitment to enhancing drug synthesis and developing novel drug targets, Rhegen aims to contribute significantly to the field of therapeutics, emphasizing both market potential and clinical value.

GenAssist Therapeutics, founded in July 2020 by a team of leading scientists and industry experts, specializes in the development of gene therapy drugs utilizing advanced base editing technology. The company is focused on addressing neuromuscular diseases that currently lack effective treatments, particularly Duchenne Muscular Dystrophy (DMD) and Spinal Muscular Atrophy (SMA). GenAssist aims to provide permanent cures by precisely repairing disease-causing genes directly within patients' cells. The company holds global intellectual property rights to its proprietary Targeted AID-based Mutagenesis (TAM) technology, positioning it at the forefront of innovative solutions for a range of genetic disorders.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

Frontera Therapeutics is a biotechnology company dedicated to developing and commercializing recombinant virus-based gene therapies. Its mission is to establish an affordable and scalable platform for producing high-quality rAAV therapies, targeting genetic disorders such as those affecting the eye, liver, metabolism, and neuromuscular systems.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

Yueer is a genomics company driven by technology, with a number of revolutionary molecular detection technologies that can reduce the sequencing cost of all NGS platforms and the sensitivity of qPCR, Sanger, and nanopore sequencing. Yueer Gene collaborates with many partners to develop affordable, timely, and accurate genetic analysis tools in order to achieve precision medicine and improve patient outcomes.

Grit Science is a biotechnology company specializing in gene therapeutics, focusing on the research and development of liver-related genetic treatments. The firm is dedicated to creating innovative medical products that address clinical needs and enhance human health. Through its commitment to advancing biopharmaceutical technology, Grit Science aims to provide effective solutions in the field of genetic medicine.

Lingyi Biology is a gene therapy company that uses a platform to validate the functionality of animal models of rare diseases. It is dedicated to sourcing innovation, with a focus on genetic rare diseases like metabolism, CNS, and ophthalmology. Lingyi Biology has a gene therapy and rare disease discovery, development, and industrialization team, as well as a rare disease animal model preparation and verification platform, to address the pain point of a lack of effective animal models for rare disease research and development.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

Geneus develops and commercializes gene sequencers and reagents. The core of its technology is based on the characteristic current signal generated by the interaction of protein nanopores and nucleic acid bases, and it realizes single-molecule nucleic acid sequencing through an integrated chip system.

Biosysen operates as a synthetic biology company specializing in species design. It employs software engineering principles to enhance biological productivity through self-replicating, scalable systems. The company's core offerings include artificial species libraries and associated pipelines tailored to specific industrial needs, with a focus on food, daily chemicals, and protein drug research and development.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

PackGene Biotech is a United States-based contract research organization and contract development and manufacturing organization that specializes in viral vectors for gene therapies. The company focuses on adeno-associated virus (AAV) vector design, cloning and packaging, as well as production of AAV, lentiviral vectors, mRNA, and plasmid DNA. It serves early-stage drug discovery, preclinical development, and cell and gene therapy trials, delivering scalable, cost-effective production with emphasis on purity, titer and infectivity. PackGene offers customized vector design, construction, and packaging services to support researchers in accelerating gene therapy programs.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

Positive Sequence Biology is a biotech company with new gene system-based editing, focused on biotech innovation & breakthrough therapies.

PackGene Biotech is a United States-based contract research organization and contract development and manufacturing organization that specializes in viral vectors for gene therapies. The company focuses on adeno-associated virus (AAV) vector design, cloning and packaging, as well as production of AAV, lentiviral vectors, mRNA, and plasmid DNA. It serves early-stage drug discovery, preclinical development, and cell and gene therapy trials, delivering scalable, cost-effective production with emphasis on purity, titer and infectivity. PackGene offers customized vector design, construction, and packaging services to support researchers in accelerating gene therapy programs.

EdiGene Inc. is a biotechnology company specializing in the development of genome editing technologies for therapeutic applications in cancer and various genetic diseases. Founded in 2015 and headquartered in Beijing, China, with additional offices in Guangzhou and Cambridge, Massachusetts, EdiGene focuses on both ex vivo and in vivo gene-editing therapies. The company has established proprietary platforms for editing hematopoietic stem cells and T cells, as well as an RNA base editing approach for in vivo applications. EdiGene's innovative methods enable targeted modifications of genetic information in human cells and facilitate high-throughput drug discovery through advanced screening techniques. By translating these technologies into novel therapeutics, EdiGene aims to improve the safety and efficacy of gene therapy, ultimately benefiting patients, the pharmaceutical industry, and the scientific research community.

Wuhan Neurophth Biotechnology Co., Ltd. is a pioneering ophthalmology gene drug research and development company based in Wuhan, China, established in 2008. It focuses on gene therapies for ocular genetic diseases, with a particular emphasis on Leber hereditary optic neuropathy (LHON), a condition caused by genetic mutations. Neurophth has made significant advancements in the field, completing the world's first clinical study of gene therapy for LHON in 2011, which involved nine patients and has since observed their progress over seven years. The company aims to develop effective treatments for various ophthalmic disorders, including degenerative optic nerve injuries and vascular retinopathy, thereby providing physicians with innovative therapeutic options for patients suffering from these conditions.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.

ViGeneron develops innovative gene therapies focused on treating ophthalmic diseases with significant unmet medical needs. Its pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms: vgAAV, enabling superior transduction efficiency and less invasive treatment administration, and REVeRT, targeting diseases caused by mutations in large genes.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.

NuProbe is a genomics and molecular diagnostics company that develops a platform of reagents and genetic toehold probes for noninvasive nucleic acid profiling. Their Sample‑In Answer‑Out solution integrates cell‑free DNA extraction, qPCR, sequencing and bioinformatics to detect mutations, CNVs, gene fusions and low‑frequency variants with high sensitivity. Founded in 2016, the company operates from Cambridge, Massachusetts and Shanghai, China, and focuses on early detection of cancer and infectious diseases for clinical and research use.

MedGenome develops sequencing-based diagnostics and a research platform that combines genomics technologies, bioinformatics, computing, and big data analytics to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases in diverse populations. The platform enables high-end genetic diagnostic tests across immuno-oncology, infectious diseases, reproductive health, and rare diseases, and serves patients, pharmaceutical companies, and research institutions worldwide by delivering deep insights into diseases at the genetic and molecular level to advance global health.

BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible. BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.

MedGenome develops sequencing-based diagnostics and a research platform that combines genomics technologies, bioinformatics, computing, and big data analytics to understand the genetic basis of cancer, metabolic disorders, eye disorders, and other rare diseases in diverse populations. The platform enables high-end genetic diagnostic tests across immuno-oncology, infectious diseases, reproductive health, and rare diseases, and serves patients, pharmaceutical companies, and research institutions worldwide by delivering deep insights into diseases at the genetic and molecular level to advance global health.

biomodal develops DNA sequencing tools and technology to enable advanced medicines, diagnostics, and personalized treatments. Its platform is designed to integrate with existing sequencing and computing platforms, enabling users to obtain complete genetic and epigenetic methylation information from DNA libraries in a single workflow.

BGI is a biotechnology company specializing in genomics. It provides genome sequencing and genetic testing services to research institutions and healthcare professionals worldwide. The company's offerings include bioinformatics, multi-omics solutions, and related tools, catering to a diverse range of clients such as pharmaceutical companies and academic institutions. BGI's work has contributed significantly to genetic and genomic research, with notable collaborations including Eli Lilly and Company, Merck, Pfizer Inc., and the Bill & Melinda Gates Foundation.